Connor Clark & Lunn Investment Management Ltd. Purchases 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 16.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 725,355 shares of the company’s stock after acquiring an additional 101,666 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Kiniksa Pharmaceuticals International were worth $28,166,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its position in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth $20,349,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after purchasing an additional 447,536 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 12,048 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer owned 16,666 shares in the company, valued at $692,638.96. This represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at approximately $520,784.46. The trade was a 61.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 80,782 shares of company stock worth $3,458,916 in the last quarter. Company insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $46.07 on Friday. The firm has a market capitalization of $3.53 billion, a P/E ratio of 62.26 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a one year low of $18.25 and a one year high of $49.12. The business has a fifty day moving average of $43.75 and a 200 day moving average of $40.58.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm’s revenue was up 65.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.12) EPS. Analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on KNSA shares. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target for the company. Finally, Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.29.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.